Chugai Pharmaceutical
Chugai Pharmaceutical
Explore linked clinical trials.25 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis | LGI1 Autoimmune Encephalitis; NMDAR Autoimmune Encephalitis | Active, not recruiting | Phase 3 | 2026-10-08 | NCT05503264 | |
| A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder | Recruiting | Phase 3 | 2026-10-06 | NCT07416604 | |
| A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-10-06 | NCT06793215 | |
| A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS) | Cytopenia, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Male Urogenital Diseases, Urogenital Diseases, anemia, atypical hemolytic-uremic syndrome, blood platelet disease, hematologic disorder, hemolytic anemia, hemolytic-uremic syndrome, kidney disorder, thrombocytopenia, thrombotic microangiopathy, uremia, urinary system disorder | Active, not recruiting | Phase 3 | 2026-10-01 | NCT04958265 | |
| A Study to Assess the Efficacy and Safety of Afimkibart for Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | Moderately to Severely Active Ulcerative Colitis | Not yet recruiting | Phase 3 | 2026-09-29 | NCT07846683 | |
| Study of AUBE00 in Patients With Solid Tumors | Solid Tumors | Recruiting | Phase 1 | 2026-09-29 | NCT07030959 | |
| A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease | Moderately to Severely Active Crohns Disease | Recruiting | Phase 3 | 2026-09-28 | NCT06819891 | |
| Clinical Trial of NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and Children | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder | Not yet recruiting | Phase 3 | 2026-09-24 | NCT07838194 | |
| A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder | Recruiting | Phase 3 | 2026-09-23 | NCT07416526 | |
| AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer | ALK Positive Non-small Cell Lung Cancer | Recruiting | Phase 1 | 2026-09-18 | NCT07617337 | |
| A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease | Moderately to Severely Active Crohns Disease | Recruiting | Phase 3 | 2026-09-16 | NCT06819878 | |
| A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-09-16 | NCT06497556 | |
| A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | Moderately to Severely Active Ulcerative Colitis | Active, not recruiting | Phase 3 | 2026-09-14 | NCT06589986 | |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease | autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myelin oligodendrocyte glycoprotein antibody-associated disease | Active, not recruiting | Phase 3 | 2026-09-04 | NCT05271409 | |
| A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors | Hemic and Lymphatic Diseases, Hemoglobinuria, Paroxysmal, anemia, bone marrow disorder, hematologic disorder, hemolytic anemia, myelodysplastic syndrome, paroxysmal nocturnal hemoglobinuria | Active, not recruiting | Phase 3 | 2026-08-18 | NCT04434092 | |
| Study of DONQ52 in Active Celiac Disease | Digestive System Diseases, Nutritional and Metabolic Diseases, celiac disease, digestive system disorder, intestinal disorder, malabsorption syndrome, metabolic disease | Recruiting | Phase 2 | 2026-08-14 | NCT07239336 | |
| A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors | Solid Tumor | Recruiting | Phase 1 | 2026-07-28 | NCT05907980 | |
| A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors | Hemic and Lymphatic Diseases, Hemoglobinuria, Paroxysmal, anemia, bone marrow disorder, hematologic disorder, hemolytic anemia, myelodysplastic syndrome, paroxysmal nocturnal hemoglobinuria | Active, not recruiting | Phase 3 | 2026-07-28 | NCT04432584 | |
| Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) | Behcet disease, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, Skin and Connective Tissue Diseases, Stomatognathic Diseases, anterior uveitis, antiphospholipid syndrome, autoimmune disease, blood coagulation disease, blood platelet disease, bullous pemphigoid, cardiovascular disorder, connective tissue disorder, dermatomyositis, eye disorder, hematologic disorder, hemorrhagic disease, hereditary disease, hereditary periodic fever syndrome, hereditary skin disorder, immune system disorder, mouth disorder, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular disease, panuveitis, polymyositis, purpura, skin disorder, skin vascular disease, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy, uveal disorder, uveitis, vascular disorder, vasculitis, vesiculobullous skin disease | Recruiting | Phase 1 | 2026-07-22 | NCT06371417 | |
| A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) | Cytopenia, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Male Urogenital Diseases, Urogenital Diseases, anemia, atypical hemolytic-uremic syndrome, blood platelet disease, hematologic disorder, hemolytic anemia, hemolytic-uremic syndrome, kidney disorder, thrombocytopenia, thrombotic microangiopathy, uremia, urinary system disorder | Active, not recruiting | Phase 3 | 2026-07-21 | NCT04861259 | |
| Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) | Behcet disease, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, Skin and Connective Tissue Diseases, Stomatognathic Diseases, anterior uveitis, antiphospholipid syndrome, autoimmune disease, blood coagulation disease, blood platelet disease, bullous pemphigoid, cardiovascular disorder, connective tissue disorder, dermatomyositis, eye disorder, hematologic disorder, hemorrhagic disease, hereditary disease, hereditary periodic fever syndrome, hereditary skin disorder, immune system disorder, mouth disorder, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular disease, panuveitis, polymyositis, purpura, skin disorder, skin vascular disease, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy, uveal disorder, uveitis, vascular disorder, vasculitis, vesiculobullous skin disease | Enrolling by invitation | Phase 1 | 2026-07-17 | NCT06723106 | |
| A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER | Extensive Stage Small Cell Lung Cancer | Recruiting | Phase 1 | 2026-02-06 | NCT07107490 | |
| A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152) | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Active, not recruiting | Phase 3 | 2025-12-31 | NCT05904886 | |
| Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma | Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, neoplasm, osteosarcoma, sarcoma | Active, not recruiting | Phase 3 | 2025-06-08 | NCT00470223 | |
| Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2025-01-30 | NCT06793553 |